A survey of more than 200 human embryonic stem cell researchers in the United States found that nearly four in ten researchers have faced excessive delay in acquiring a human embryonic stem cell line and that more than one-quarter were unable to acquire a line they wanted to study.
Researchers at Rensselaer Polytechnic Institute have developed a new method to design antibodies aimed at combating disease. The surprisingly simple process was used to make antibodies that neutralize the harmful protein particles that lead to Alzheimer’s disease.
A key protein that controls how the deadly plant poison and bioweapon ricin kills, has finally been identified by researchers at the Institute of Molecular Biotechnology in Vienna, Austria. The discovery was made using a revolutionary new technology that combines stem cell biology and modern screening methods.
Using reprogrammed cells and microthreads, scientists at WPI and CellThera open the door for a new clinical therapy to treat major muscle trauma.
Tailor-made synthetic tracheal scaffold called “an urgent clinical need.”
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
A team of Vanderbilt chemists have designed and successfully synthesized the largest artificial protein using a new approach that greatly expands scientists’ ability to create proteins unknown in nature.
A compound that mimics the effects of adiponectin, a beneficial protein that is produced by fat tissue in healthy weight individuals and may exhibit protective effects against cancer, cardiovascular disease, inflammatory conditions and insulin resistance has been developed by an international consortium.
Any way you slice it, bread with critical nutrients could help combat severe malnutrition in impoverished regions. That is the goal of a group of Johns Hopkins undergraduate students who are enhancing common yeast so that it produces bread that yields Vitamin A. .
Injectable substance made with proteins enables tissue to grow new blood vessels.
A new study demonstrates that mechanical forces affect the growth and remodeling of blood vessels during tissue regeneration and wound healing. The forces diminish or enhance the vascularization process and tissue regeneration depending on when they are applied during the healing process.
A genetically engineered clotting factor that controlled hemophilia in an animal study offers a novel potential treatment for human hemophilia and a broad range of other bleeding problems.
In the film Contagion, a virus outbreak occurs, killing thousands of people all over the world. In the final scene we discover that the global outbreak started after a fruit bat infected a pig. Complete fiction? Actually, there may be some elements of truth to it.
The prospect of doing human clinical trials with stem cells to treat diseases like multiple sclerosis may be growing closer, say scientists at UB and U of R who have developed a more precise way to isolate stem cells that will make myelin.
Researchers at the La Jolla Institute for Allergy & Immunology have identified a previously unknown mechanism that generates protective immune memory cells to fight recurring infections at the body’s mucosal linings – which include the mouth, the intestines, the lungs and other areas. These are the main entry points for many viruses and other infectious organisms.
University of Maryland researchers patented and licensed a “Bio-glue” that allows simulation of mechanical and chemical heartbeats from a single cell.
Using a modern version of open-wide-and-keep-this-under-your-tongue, scientists today reported taking the temperature of individual cells in the human body, and finding for the first time that temperatures inside do not adhere to the familiar 98.6 degree Fahrenheit norm. They presented the research at the 242nd National Meeting & Exposition of the American Chemical Society (ACS), being held here this week.
Using an unusual human cell line of this type, Whitehead Institute researchers and their collaborators performed a genetic screen and identified a protein used by Ebola virus to gain entry into cells and begin replicating. The discovery may offer a new approach for the development of antiviral therapeutics.
For the first time ever, scientists are using computers and genomic information to predict new uses for existing medicines. A National Institutes of Health-funded computational study analyzed genomic and drug data to predict new uses for medicines that are already on the market.
Scientists at the University of North Carolina at Chapel Hill School of Medicine have devised a gene therapy cocktail that has the potential to treat some inherited diseases associated with “misfolded” proteins.
For decades, scientists have studied a laboratory mouse model that develops signs of the paralyzing disease amyotrophic lateral sclerosis (ALS) as they age. In a new study appearing in Nature Biotechnology, investigators at Nationwide Children’s Hospital have developed a new model of ALS, one that mimics sporadic ALS, which represents about 90 percent of all cases.
Researchers have built the first functional anal sphincters in the laboratory, suggesting a potential future treatment for both fecal and urinary incontinence.
Each year, plant diseases wipe out millions of tons of crops and waste valuable water resources. But a new discovery suggests that all pathogens attack plants via a surprisingly limited number of cellular targets. The finding could help researchers develop disease resistant crops and environmentally sustainable treatments for plant diseases.
Researchers who have been working for nearly a decade to piece together the process by which an enzyme repairs sun-damaged DNA have finally witnessed the entire process in full detail in the laboratory.
The discovery of the mechanism of action behind a novel class of anticancer drugs designed to disrupt cancer cell mitochondrial metabolism may be a major step toward furthering clinical trials of the agents.
Researchers at Albert Einstein College of Medicine of Yeshiva University have developed the first fluorescent protein that enables scientists to clearly "see" the internal organs of living animals without the need for a scalpel or imaging techniques that can have side effects or increase radiation exposure.
Researchers at Dana-Farber Cancer Institute have demonstrated a molecular strategy they say could make a much larger variety of tumors treatable with PARP inhibitors, a promising new class of cancer drugs.
A recent Kavli Futures Symposium focused on the progress, and promise, of evolving biological functions in the lab. Now, three Symposium participants discuss this remarkable research, and how it's drawing together diverse scientific fields.
A computer-based diabetes simulation tool developed by University of Virginia researchers is now commercially available, thanks to a partnership with Charlottesville-based medical research firm The Epsilon Group. The protocol is approved by the FDA as an alternative to animal testing of Type 1 diabetes control strategies.
According to the CDC, about 20 percent of Americans with HIV don’t know it, greatly increasing their risk of transmitting the virus.
The drug Incivek, when given in combination with two other medications, can dramatically increase the chances of people chronically infected with untreated genotype 1 hepatitis C virus achieving a viral cure.
Veritract, a University of Utah startup company, is developing a “Smart Feeding Tube” with a live camera and steering mechanism that enables doctors to place feeding tubes with much more accuracy than current technology allows. The company has just received $820,000 in an early round of funding.
Mayo Clinic investigators and collaborators from the United Kingdom cured well-established prostate tumors in mice using a human vaccine with no apparent side effects. This novel cancer treatment approach encourages the immune system to rid itself of prostate tumors without assistance from toxic chemotherapies and radiation treatments. Such a treatment model could some day help people to live tumor free with fewer side effects than those experienced from current therapies.
Biogen Idec is working with the NC State Poole College of Management's Executive Programs to develop the organization's future leaders in its pharmaceutical operations and technology business unit.
Now a new study reports that reovirus has the potential to treat certain lung cancer patients, when the reovirus is combined with two other substances known as paclitaxel and carboplatin.
It has been an exciting time for Rensselaer Polytechnic Institute student Kinsley French. During the Rensselaer commencement, French was awarded the J. Erik Jonsson Prize for her perfect 4.0 grade point average and high-caliber undergraduate research. She earned a dual major in mathematics and biology in just three and a half years.
A mutant gene long thought to accelerate tumor growth in thyroid cancer patients actually inhibits the spread of malignant cells, showing promise for novel cancer therapies, a Mayo Clinic study has found.
For cooperation to persist in the often violently competitive realm of bacteria, cheaters must be kept in line. Two Indiana University Bloomington biologists have learned that in one bacterium, at least, bacterial cooperators can evolve to "police" the cheaters and arrest their bids for dominance.
Seattle BioMed’s Aderem shares Insight into rational vaccine development using new approaches.
A group led by University of Wisconsin-Madison stem cell researcher Su-Chun Zhang reports it has been able to direct embryonic and induced human stem cells to become astrocytes in the lab dish.
The Center for Biotechnology (CFB) at Stony Brook University has established the Biotechnology Commercialization Fund to accelerate the development of promising biomedical technologies emerging from Stony Brook University. Created with support from the New York State Foundation for Science, Technology, and Innovation (NYSTAR) and the Office of the Vice President for Research at Stony Brook University, the Fund will immediately help develop six technologies in partnership with researchers University-wide.
A discovery reported from the University of Wisconsin-Madison suggests that micrometer-sized droplets of liquid crystal, which have been found to change their ordering and optical appearance in response to the presence of very low concentrations of a particular bacterial lipid, might find new uses in a range of biological contexts.
Grantees honored as finest in field of biotechnology.
Scientists at the Sahlgrenska Academy have discovered an explanation of how stroke patients can achieve better recovery. A hormone that is associated with the growth hormone system has proved to benefit recovery during the later phases of rehabilitation after a stroke.
A uniquely collaborative study by researchers at the Salk Institute for Biological Studies uncovered a novel mechanism that turns up glucose production in the liver when blood sugar levels drop, pointing towards a new class of drugs for the treatment of metabolic disease.
Boston University researchers discover that a simple compound — sugar – dramatically boosts the effectiveness of first-line antibiotics. Their findings appear in the May 12 issue of Nature.
A common, tiny tropical fish plays a key role in a new model for Cushing disease, giving researchers a powerful tool to conduct extensive searches for effective treatments for this serious hormonal disorder, testing up to 300 drugs weekly.
An international team of researchers led by scientists at Scripps Institution of Oceanography at UC San Diego has deciphered the genome of a tropical marine organism known to produce substances potentially useful against human diseases.
UCLA scientists have discovered a way to wake up the immune system to fight cancer by delivering an immune system-stimulating protein in a nanoscale container called a vault directly into lung cancer tumors, harnessing the body’s natural defenses to fight disease growth.
Only about half of new drugs approved in the last decade had comparative effectiveness data available at the time of their approval by the U.S. Food and Drug Administration, and approximately two-thirds of new drugs had this information available when alternative treatment options existed, according to a study in the May 4 issue of JAMA.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right